Floatz logo

rp903

Solid Tumor Cancer

Risen (Suzhou) Pharma Tech Co., Ltd.Phase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

42 Active assets in the Solid Tumor Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Sarcoma Oncology Research Center, LLC
Phase 2CCC
Zofran
GlaxoSmithKline
Phase 3CCC
DEXAMETHASONE
GlaxoSmithKline
Phase 3CCC
Casopitant
GlaxoSmithKline
Phase 3CCC
MITOMYCIN C
Sarcoma Oncology Research Center, LLC
Phase 2CCC

View all 50 →

Same molecule, other indications

rp903 is also rated in:

cervical cancerDormant
CC
Indicative ·
40 / 100
View asset →
endometrial carcinomaDormant
CC
Indicative ·
40 / 100
View asset →
ovarian cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →